LECANEMAB-IRMB (LEQEMBI)

LECANEMAB-IRMB (LEQEBMI) is an amyloid beta-directed antibody indicated for the treatment of Alzheimer's disease in patients with mild cognitive impairment or mild dementia stage of disease.

Indication:

Mild cognitive impairment due to Alzheimer's disease
Mild Alzheimer's disease dementia, with confirmed amyloid pathology

Injection Duration:

Frequency:

Every two weeks. (At least 14 days apart)

schedule a consultation